What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock SaleThe Motley Fool • 01/11/26
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity DrugZacks Investment Research • 01/09/26
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in ObesityPRNewsWire • 01/08/26
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial OfficerPRNewsWire • 01/07/26
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 01/05/26
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/26
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.Market Watch • 01/05/26
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase IIIZacks Investment Research • 01/02/26
Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks RemainSeeking Alpha • 12/28/25
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 12/23/25
Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking TherapeuticsInvestors Business Daily • 12/04/25
VKTX Stock Rises 34% in Three Months: Here's What You Should KnowZacks Investment Research • 12/01/25
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare ConferencePRNewsWire • 11/25/25
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 11/21/25